Accessible Unlicensed Requires Authentication Published online by De Gruyter October 21, 2021

Novel thiazolyl-hydrazone derivatives including piperazine ring: synthesis, in vitro evaluation, and molecular docking as selective MAO-A inhibitor

Derya Osmaniye ORCID logo, Ramazan Alaşan, Begüm Nurpelin Sağlık ORCID logo, Serkan Levent, Yusuf Özkay and Zafer Asım Kaplancıklı


MAO-A inhibitors are used in the treatment of depression. There are many studies showing that the thiazolyl-hydrazone structure is a pharmacophore structure for the MAO enzyme. In previous studies by our team, activity studies were carried out with thiazolyl-hydrazone derivatives containing pyrrolidine, morpholine, and piperazine. All of them were displayed MAO-A selective inhibition profile. Additionally, derivatives containing piperazine ring were most active. For this purpose, thiazolyl-hydrazone derivatives containing piperazine were synthesized, but this time an active group, formyl group, was added to the piperazine ring as a substituent. Based on this view, new thiazolyl-hydrazone compounds were synthesized, characterized, and screened for their hMAO-A and hMAO-B inhibitory activity by an in vitro fluorometric method. The structure of the compound was tried to be fully elucidated using 2D NMR technique. The compound including 2,4-dimethyl substituent (3i) were found to be the most effective agents in the series against MAO-A enzyme with the IC50 value of 0.080 ± 0.003 µM. The docking study of compound 3i revealed that there is a strong interaction between the active sites of hMAO-A and analyzed compound.

Corresponding author: Derya Osmaniye, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir26470, Turkey; and Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir26470, Turkey, E-mail:

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.


1. Ruan, B-F, Cheng, H-J, Ren, J, Li, H-L, Guo, L-L, Zhang, X-X, et al.. Novel 2H-chromen-2-one derivatives of resveratrol: design, synthesis, modeling and use as human monoamine oxidase inhibitors. Eur J Med Chem 2015;103:185–90. in Google Scholar

2. Ferrazzano, L, Viola, A, Lonati, E, Bulbarelli, A, Musumeci, R, Cocuzza, C, et al.. New isoxazolidinone and 3, 4-dehydro-β-proline derivatives as antibacterial agents and MAO-inhibitors: a complex balance between two activities. Eur J Med Chem 2016;124:906–19. in Google Scholar

3. Yang, X-G, Mou, Y-H, Wang, Y-J, Wang, J, Li, Y-Y, Kong, R-H, et al.. Design, synthesis, and evaluation of monoamine oxidase a inhibitors–indocyanine dyes conjugates as targeted antitumor agents. Molecules 2019;24:1400. in Google Scholar

4. Tzvetkov, NT, Stammler, H-G, Neumann, B, Hristova, S, Antonov, L, Gastreich, M. Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem 2017;127:470–92. in Google Scholar

5. Khattab, SN, Khalil, HH, Bekhit, AA, El-Rahman, MMA, El-Faham, A, Albericio, F. Synthesis and preliminary biological evaluation of 1, 3, 5-triazine amino acid derivatives to study their MAO inhibitors. Molecules 2015;20:15976–88. in Google Scholar

6. Guglielmi, P, Carradori, S, Poli, G, Secci, D, Cirilli, R, Rotondi, G, et al.. Design, synthesis, docking studies and monoamine oxidase inhibition of a small library of 1-acetyl-and 1-thiocarbamoyl-3, 5-diphenyl-4, 5-dihydro-(1H)-pyrazoles. Molecules 2019;24:484. in Google Scholar

7. Saddique, FA, Zaib, S, Jalil, S, Aslam, S, Ahmad, M, Sultan, S, et al.. Synthesis, monoamine oxidase inhibition activity and molecular docking studies of novel 4-hydroxy-N′-[benzylidene or 1-phenylethylidene]-2-H/methyl/benzyl-1, 2-benzothiazine-3-carbohydrazide 1, 1-dioxides. Eur J Med Chem 2018;143:1373–86. in Google Scholar

8. Can, NÖ, Osmaniye, D, Levent, S, Sağlık, BN, Inci, B, Ilgın, S, et al.. Synthesis of new hydrazone derivatives for MAO enzymes inhibitory activity. Molecules 2017;22:1381. in Google Scholar

9. Tripathi, AC, Upadhyay, S, Paliwal, S, Saraf, SK. Privileged scaffolds as MAO inhibitors: retrospect and prospects. Eur J Med Chem 2018;145:445–97. in Google Scholar

10. Dhiman, P, Malik, N, Sobarzo-Sánchez, E, Uriarte, E, Khatkar, A. Quercetin and related chromenone derivatives as monoamine oxidase inhibitors: targeting neurological and mental disorders. Molecules 2019;24:418. in Google Scholar

11. Kukula-Koch, W, Koch, W, Czernicka, L, Głowniak, K, Asakawa, Y, Umeyama, A, et al.. MAO-A inhibitory potential of terpene constituents from ginger rhizomes—a bioactivity guided fractionation. Molecules 2018;23:1301. in Google Scholar

12. Xiao, X, Zhang, X-X, Zhan, M-M, Cheng, K, Li, S, Xie, Z, et al.. Design, synthesis and bioevalucation of novel 2, 3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline. Eur J Med Chem 2018;145:588–93. in Google Scholar

13. Ramsay, RR, Tipton, KF. Assessment of enzyme inhibition: a review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs. Molecules 2017;22:1192. in Google Scholar

14. Secci, D, Carradori, S, Petzer, A, Guglielmi, P, D’Ascenzio, M, Chimenti, P, et al.. 4-(3-Nitrophenyl) thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis. J Enzym Inhib Med Chem 2019;34:597–612. in Google Scholar

15. D’Ascenzio, M, Chimenti, P, Gidaro, MC, De Monte, C, De Vita, D, Granese, A, et al.. (Thiazol-2-yl) hydrazone derivatives from acetylpyridines as dual inhibitors of MAO and AChE: synthesis, biological evaluation and molecular modeling studies. J Enzym Inhib Med Chem 2015;30:908–19. in Google Scholar

16. Chimenti, P, Petzer, A, Carradori, S, D’Ascenzio, M, Silvestri, R, Alcaro, S, et al.. Exploring 4-substituted-2-thiazolylhydrazones from 2-, 3-, and 4-acetylpyridine as selective and reversible hMAO-B inhibitors. Eur J Med Chem 2013;66:221–7. in Google Scholar

17. Carradori, S, Secci, D, D’Ascenzio, M, Chimenti, P, Bolasco, A. Microwave and ultrasound‐assisted synthesis of thiosemicarbazones and their corresponding (4, 5‐Substituted‐thiazol‐2‐yl) hydrazines. J Heterocycl Chem 2014;51:1856–61. in Google Scholar

18. Chimenti, F, Secci, D, Bolasco, A, Chimenti, P, Granese, A, Carradori, S, et al.. Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene) hydrazines. J Med Chem 2010;53:6516–20. in Google Scholar

19. Chimenti, F, Bolasco, A, Secci, D, Chimenti, P, Granese, A, Carradori, S, et al.. Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors. Bioorg Med Chem 2010;18:5715–23. in Google Scholar

20. Chimenti, F, Secci, D, Bolasco, A, Chimenti, P, Granese, A, Carradori, S, et al.. Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem 2010;18:5063–70. in Google Scholar

21. Chimenti, F, Secci, D, Bolasco, A, Chimenti, P, Granese, A, Carradori, S, et al.. Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4, 5-substituted-thiazol-2-yl) hydrazones. MedChemComm 2010;1:61–72. in Google Scholar

22. Can, NÖ, Osmaniye, D, Levent, S, Sağlık, BN, Korkut, B, Atlı, Ö, et al.. Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors. Eur J Med Chem 2018;144:68–81. in Google Scholar

23. Sağlık, BN, Cebeci, O, Acar Çevik, U, Osmaniye, D, Levent, S, Kaya Çavuşoğlu, B, et al.. Design, synthesis, in vitro and in silico studies of new thiazolylhydrazine-piperazine derivatives as selective MAO-A inhibitors. Molecules 2020;25:4342.Search in Google Scholar

24. Sağlık, BN, Çavuşoğlu, BK, Osmaniye, D, Levent, S, Çevik, UA, Ilgın, S, et al.. In vitro and in silico evaluation of new thiazole compounds as monoamine oxidase inhibitors. Bioorg Chem 2019;85:97–108. in Google Scholar

25. Can, ÖD, Osmaniye, D, Özkay, ÜD, Sağlık, BN, Levent, S, Ilgın, S, et al.. MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains. Eur J Med Chem 2017;131:92–106. in Google Scholar

26. Ilgın, S, Osmaniye, D, Levent, S, Sağlık, BN, Acar Çevik, U, Çavuşoğlu, BK, et al.. Design and synthesis of new benzothiazole compounds as selective hMAO-B inhibitors. Molecules 2017;22:2187.Search in Google Scholar

27. Tok, F, Uğraş, Z, Sağlık, BN, Özkay, Y, Kaplancıklı, ZA, Koçyiğit-Kaymakçıoğlu, B. Novel 2, 5-disubstituted-1, 3, 4-oxadiazole derivatives as MAO-B inhibitors: synthesis, biological evaluation and molecular modeling studies. Bioorg Chem 2021;112:104917. in Google Scholar

28. Tok, F, Sağlık, BN, Özkay, Y, Ilgın, S, Kaplancıklı, ZA, Koçyiğit-Kaymakçıoğlu, B. Synthesis of new hydrazone derivatives and evaluation of their monoamine oxidase inhibitory activity. Bioorg Chem 2021;114:105038. in Google Scholar

29. Son, S-Y, Ma, J, Kondou, Y, Yoshimura, M, Yamashita, E, Tsukihara, T. Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci Unit States Am 2008;105:5739–44. in Google Scholar

Supplementary Material

The online version of this article offers supplementary material (

Received: 2021-08-19
Accepted: 2021-09-30
Published Online: 2021-10-21

© 2021 Walter de Gruyter GmbH, Berlin/Boston